대한한방부인과학회지 (The Journal of Korean Obstetrics and Gynecology)

  • 제31권3호
  • /
  • Pages.152-163
  • /
  • 2018
  • /
  • 1229-4292(pISSN)
  • /
  • 2508-3619(eISSN)
대한한방부인과학회 (The Society of Korean Medicine Obstetrics and Gynecology)
권호 표지
DOI QR코드

DOI QR Code

AMH 수치가 상승된 희발월경 환자 증례보고

A Case Study on Korean Medicine Treatment for the Oligomenorrhea with Increased Anti-mullerian Hormone Level

  • 홍가경 (원광대학교 한의과대학 한방부인과학교실) ;
  • 강수진 (원광대학교 한의과대학 한방부인과학교실) ;
  • 김선경 (원광대학교 한의과대학 한방부인과학교실) ;
  • 김송백 (원광대학교 한의과대학 한방부인과학교실)
  • Hong, Ka-Kyung (Dept. of OB & GY, College of Oriental Medicine, Wonkwang University) ;
  • Kang, Su-Jin (Dept. of OB & GY, College of Oriental Medicine, Wonkwang University) ;
  • Kim, Sun-Kyung (Dept. of OB & GY, College of Oriental Medicine, Wonkwang University) ;
  • Kim, Song-Baek (Dept. of OB & GY, College of Oriental Medicine, Wonkwang University)
  • 투고 : 2018.07.13
  • 심사 : 2018.08.22
  • 발행 : 2018.08.24
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: In recent studies, increased AMH level has been suggested as objective surrogate marker for diagnosis PCOS, one of the major causes of oligomenorrhea. The purpose of this study is to report the clinical effect of Korean medicine treatment on oligomenorrhea patient with increased Anti-mullerian hormone level, who can be diagnosed who can be ruled out PCOS. Methods: A 27 year old woman with oligomenorrhea was enrolled in this study. We measured serum hormone levels and ruled out PCOS. The patient received Korean medicine treatment for 3 months, we assessed the result of treatment through observation of the menstrual cycle and follow-up measurements of serum hormone levels. Results: 1. The patient had menstrual cycle regularly. 2. Increased serum AMH level of the patient decreased from 12.16 ng/ml to 8.51 ng/ml. 3. The other serum hormone levels such as testosterone, LH/FSH ratio decreased Conclusion: This case shows that Korean medicine treatment could have a beneficial effect on menstrual cycle and decrease the increased serum hormone levels of ruled out PCOS patient.

키워드

참고문헌

  1. Korean Society of Obstetrics and Gynecology. Gynecology. 5th ed. Seoul: Korea Medical Book Publishing Company. 2015:81-493.
  2. The society of Korean medicine obstetrics and gynecology. Korean medicine obstetrics and gynecology. 3rd ed. Seoul:Uiseongdang. 2016:31-191.
  3. Kim JH, et al. A Study on the Characters of Oligomenorrheic Patients by Through Comparison of BMI, Yangorak, Menarche of Normal Menstrual Cycle Group and Oligomenorrheic Group. The Journal of Oriental Obstetrics & Gynecology. 2011;24(3):85-97.
  4. Lee HY, Sung YH. Epidemiology and Diagnostic Criteria of Polycystic Ovary Syndrome. J Korean Diabetes. 2015;16(3):189-93. https://doi.org/10.4093/jkd.2015.16.3.189
  5. You SY, et al. Anti-mullerian Hormone in Women with Polycystic Ovary Syndrome. Korean J obestet Gynecol. 2012;55(5):315-24. https://doi.org/10.5468/KJOG.2012.55.5.315
  6. Dumont A, et al. Role of Anti-Mullerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reproductive Biology and Endocrinology. 2015;13(1):137. https://doi.org/10.1186/s12958-015-0134-9
  7. Song DK, et al. Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Mullerian hormone cutoff value. Korean J Intern Med. 2017;32(4):690-8. https://doi.org/10.3904/kjim.2016.038
  8. Dewailly D, et al. Reconciling the Definitions of Polycystic Ovary Syndrome: The Ovarian Follicle Number and Serum Anti-Mullerian Hormone Concentrations Aggregate with the Markers of Hyperandrogenism. J Clin Endocrinol Metab. 2010;95(9):4399-405. https://doi.org/10.1210/jc.2010-0334
  9. Sung YH. Medical Diagnosis and Treatment of Polycystic Ovary Syndrome. The Korean Journal of Medicine. 2006;70(4):356-60.
  10. Balen A, Conway G, Kaltsas G. Polycystic Ovary Syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10(8):2107-11. https://doi.org/10.1093/oxfordjournals.humrep.a136243
  11. Sirmans SM, Pate KA. Epidemiology, Diagnosis, and Management of Polycystic Ovary Syndrome. Clinical Epidemiology. 2013;6(default):1-13.
  12. Sung YA. Polycystic Ovary Syndrome in Korean Women: Clinical Characteristics and Diagnostic Criteria. Enadocrinol Metab. 2011;26(3):203-7. https://doi.org/10.3803/EnM.2011.26.3.203
  13. Fauser B, et al. Consensus on Women's Health Aspects of Polycystic Ovary Syndrome(PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group. Fertil Steri. 2012;97(1):28-38.e25. https://doi.org/10.1016/j.fertnstert.2011.09.024
  14. Yun SY, Kang MJ. Clinical Study of Oriental Medicine Treatment for Polycystic Ovarian Disease. The Journal Of Oriental Obstetrics & Gynecology. 2000;13(2):437-51.
  15. Bili H. et al. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years. Eur J Endocrinol. 2001;145(6):749-55. https://doi.org/10.1530/eje.0.1450749
  16. Moran C, et al. Adrenal androgen excess and body mass index in polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100(3):942-50. https://doi.org/10.1210/jc.2014-2569
  17. Lee JR, Kim SH. Anti-Mullerian hormone and female reproduction. Korean J Obstet Gynecol. 2009;52(3):285-300.
  18. La Marca A, et al. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril. 2004;82(4):970-2. https://doi.org/10.1016/j.fertnstert.2004.06.001
  19. Pigny P, et al. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(3):941-5. https://doi.org/10.1210/jc.2005-2076
  20. Li L, et al. Elevated serum antimullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien Klin Wochenschr. 2010;122(17-18):519-24. https://doi.org/10.1007/s00508-010-1426-x
  21. Woo HY, et al. Differences of the association of anti-Mullerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr J. 2012;59(9):781-90. https://doi.org/10.1507/endocrj.EJ12-0055
  22. Mun JB. Usefulness of Anti-mullerian Hormone for the Diagnosis of Polycystic Ovary Syndrome. Department of Medicine, Graduate school, Wonkwang university. 2014.
  23. Seopgye(葉桂). Seopcheonsayeogwa(葉天士女科). Seoul:Daeseongmunhwasa. 1995:14-5.
  24. Shin MK. Clinical Traditional Herbalogy. 2nd rev. ed. Seoul:Youngrimsa. 2010:213-558.
  25. Oh TG, et al. Clinical Study for the One Case that Diagnosed Polycystic Ovarian Disease. The Journal Of Oriental Obstetrics & Gynecology. 2008;21(2):284-91.
  26. Kim JR, et al. Clinical Study for the Four Cases of Secondary Amenorrhea and Hypomenorrhea by Hormone Assay. The Journal Of Oriental Obstetrics & Gynecology. 2009;22(3):267-76.